Dr. Chris Chen is Chief Executive Officer of WuXi Biologics, a Hong Kong-listed company with a market cap surpassing $25 billion. Under his leadership, WuXi Biologics has built a world-class open-access integrated biologics discovery, development and manufacturing platform enabling a full spectrum of companies ranging from boutique virtual enterprises to Top 20 global pharmaceutical companies. During Dr. Chen’s tenure, WuXi Biologics has assembled one of the world’s largest biologics teams, with over 5,800 employees enabling 80 Investigational New Drug (IND) programs and 7 Biologics License Application (BLA) programs per year.

Prior to his role at WuXi Biologics, Dr. Chen served as Chief Operating Officer at Celgene Biopharmaceuticals, where he led the successful development of a high-tier, high-quality commercial process for biosimilar etanercept. He previously held leadership positions at Eli Lilly and Merck.

Dr. Chen’s extensive experience in monoclonal antibodies (mAb), therapeutic proteins and vaccines has been recognized by industry leaders. Dr. Chen serves on the International Board of Directors for the International Society for Pharmaceutical Engineering (ISPE), and is the first board member from Asia. In addition, he has chaired multiple conferences in biochemical engineering and mAb development in the U.S. and China, and is frequently invited to speak at conferences. He is also an adjunct professor at Shanghai Jiao Tong University. Dr. Chen is the co-author and co-inventor of over 70 publications and patents.

Dr. Chen obtained bachelor’s degrees in chemical engineering and automation from Tsinghua University and his Ph.D. in chemical engineering from the University of Delaware.